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. Preamble
.1. Need for developing case deﬁnitions and guidelines for data
ollection, analysis, and presentation for the hypertensive
isorders of pregnancy as adverse events following immunization
There is no universally accepted case deﬁnition of gestational
ypertension, preeclampsia or eclampsia that occurs following
mmunisations. This is a missed opportunity, as data comparability
cross trials or surveillance systems would facilitate data interpre-
ation and promote the scientiﬁc understanding of the event. As
mmunization is considered an essential element of care in preg-
ancy, the potential complications of this procedure should be
nderstood. Additionally, vaccine studies may  be conducted in a
ariety of settings, including those with fewer resources to per-
orm the same diagnostic testing as in higher resource settings. It
s important to provide deﬁnitions that can be utilized widely.
∗ Corresponding author at: Brigham & Women’s Hospital, 75 Francis Street,
oston, MA  02115, USA. Tel.: +1 617 732 5435.
E-mail address: contact@brightoncollaboration.org (T.F. McElrath).
1 Brighton Collaboration homepage: http://www.brightoncollaboration.org.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.038
264-410X/© 2016 Published by Elsevier Ltd. This is an open access article under the CC BAround 10% of all pregnant women will be affected by a hyper-
tensive disorder during pregnancy [1]. Hypertensive disorders of
pregnancy are a signiﬁcant contributor to maternal and neonatal
morbidity and mortality, and are implicated in 10–15% of mater-
nal deaths worldwide [1,2]. The exact mechanism responsible
for hypertensive diseases of pregnancy, in particular preeclamp-
sia, is not known. One leading hypothesis is that abnormalities
in the development of the uteroplacental unit lead to increased
hypoxemia and oxidative stress, which in turn lead to endothe-
lial dysfunction and abnormalities in vascular tone and coagulation
[3,4].
Hypertensive disease in pregnancy encompasses a spectrum
of conditions, including gestational hypertension, preeclampsia
(which can be further qualiﬁed as having severe features), eclamp-
sia, chronic hypertension with superimposed preeclampsia and
HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelets) syn-
drome. Because of differences among the guidelines issued by
international societies, diagnosis can occasionally become con-
fusing as terminology may  vary. Nevertheless, it is important to
differentiate hypertensive disorders that predate pregnancy from
those that occur during pregnancy, as well as to categorize patients
into more or less serious cases. Furthermore, the speciﬁc diagnosis
has important treatment implications, such as timing of delivery.
Y license (http://creativecommons.org/licenses/by/4.0/).
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he deﬁnitive treatment for hypertensive diseases of pregnancy is
elivery.
The association of vaccination with the hypertensive diseases
f pregnancy has not been well studied and the exact incidence is
ot known. There are observational studies as well as case reports
f hypertensive disease developing in women after vaccine admin-
stration but no causal link has been described. Furthermore, the
ase deﬁnitions for the observational studies are not well deﬁned,
ith several studies relying solely on ICD-9 codes.
.2. Methods for the development of the case deﬁnition and
uidelines  for data collection, analysis, and presentation for the
ypertensive  disorders of pregnancy as adverse events following
mmunization
Following the process described in the overview paper [5]
s well as on the Brighton Collaboration Website, http://www.
rightoncollaboration.org/internet/en/index/process.html, the
righton Collaboration Preeclampsia Working Group was  formed
n 2015 and included members with clinical, academic and public
ealth background. The composition of the working and reference
roup as well as results of the web-based survey completed by the
eference group with subsequent discussions in the working group
an be viewed at: http://www.brightoncollaboration.org/internet/
n/index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
ines, a literature search of publications in English was  performed
sing Medline, Embase and the Cochrane Libraries, including the
erms vaccines, vaccination, or immunization (or terms beginning
ith vaccin-, immuni-, inoculat-), and [hypertension AND preg-
ancy] or [preeclampsia or eclampsia] (or preeclam-, eclamp-). The
earch resulted in the identiﬁcation of 516 references. All abstracts
ere screened for possible reports of preeclampsia, eclampsia or
ypertension in pregnancy following immunization. Twenty-seven
rticles with potentially relevant material were reviewed in more
etail, in order to identify studies using case deﬁnitions or, in their
bsence, providing clinical descriptions of the case material. Data
ollected from these 27 articles included information on the study
ype, the vaccine, the diagnostic criteria or case deﬁnition put forth,
he time interval since time of immunization, and any other symp-
oms. References that lacked hypertensive diseases of pregnancy
s an outcome were excluded.
Most publications were of observational studies, though there
ere also several publications from vaccine adverse event repor-
ing groups. Only one publication [6] speciﬁed the criteria used
o diagnose preeclampsia in study participants. Four of the pub-
ications reported using ICD-9 diagnostic codes to collect cases
f preeclampsia/eclampsia or pregnancy related hypertension
2,7–9].
.3. Rationale for selected decisions about the case deﬁnition of
reeclampsia  as an adverse event following immunization
.3.1. The terms for hypertension in pregnancy
The terms “eclampsia,” “preeclampsia,” “gestational hyperten-
ion” and “pregnancy-induced hypertension” are commonly used
n clinical practice. “Pregnancy-induced hypertension” is a term
eferring to hypertensive disorders of pregnancy in general, but
acks the speciﬁcity of the other terms, and so the Brighton
eﬁnitions will refer only to “eclampsia,” “preeclampsia,” and
gestational hypertension.” All of these disorders are character-
zed by elevations in blood pressure. Preeclampsia and eclampsia
C.E. Rouse et al. / Va070ave additional diagnostic criteria based on laboratory ﬁndings
y clinical physical exam or patient reported symptoms reﬂect-
ng the systemic nature of the disease. The diagnosis of gestational
ypertension is provisional, in that every woman with new bloodpressure  elevation in pregnancy should be further evaluated for the
development of preeclampsia. It is possible to move from a diagno-
sis of gestational hypertension to preeclampsia or eclampsia, but
not from preeclampsia to gestational hypertension.
1.3.2. Formulating a case deﬁnition that reﬂects diagnostic
certainty: weighing speciﬁcity versus sensitivity
The number of symptoms and/or signs that will be documented
for each case may  vary considerably. The case deﬁnitions have been
formulated such that the Level 1 deﬁnition is highly speciﬁc for
the condition. As maximum speciﬁcity normally implies a loss of
sensitivity, one additional diagnostic levels have been included in
the deﬁnition, offering a stepwise increase of sensitivity from Level
1 down to Level 2, while retaining an acceptable level of speciﬁcity
at all levels. In this way  it is hoped that all possible cases of the
hypertensive diseases of pregnancy can be captured.
It needs to be emphasized that the grading of deﬁnition lev-
els is entirely about diagnostic certainty, not clinical severity of
an event. Thus, a clinically very severe event may  appropriately
be classiﬁed as Level 2 rather than Level 1 if it could reasonably
be ascribed to an etiology other than the hypertensive diseases of
pregnancy. Detailed information about the severity of the event
should additionally be recorded, as speciﬁed by the data collection
guidelines.
1.3.3. The timing of development of preeclampsia in the context
of  vaccine administration
Preeclampsia and gestational hypertension are conventionally
deﬁned as developing after 20 weeks gestation [10], but there
can be great variability in exact timing of presentation of the
disease. In one study, approximately 10% of the preeclampsia diag-
noses were made before 34 weeks gestation [11]. Preeclampsia
can develop up to 6 weeks postpartum and, in fact, 20–50% of
eclampsia occurs in the postpartum period [12,13]. The progres-
sion from normal blood pressure to hypertension to preeclampsia
can proceed rapidly, gradually, or not at all. Because of the unpre-
dictability in development and progression of the disease, it is
important for the purpose of vaccine trials to record the tempo-
ral relationship between immunization and development of any
preeclampsia-related complication of pregnancy.
1.3.4. Rationale for individual criteria related to the case
deﬁnition
1.3.4.1. Gestational hypertension. Gestational hypertension refers
to new onset hypertension after 20 weeks of gestation [10,14,15].
The use of “20 weeks gestation” as a diagnostic criterion is some-
what arbitrary, as there is no speciﬁc physiologic change known
that occurs at this gestational age that permits the development of
preeclampsia. However, given that this convention is widely used,
the Brighton Collaboration will continue to utilize it for the sake of
continuity.
Accurate blood pressure measurement is fundamental for the
diagnosis of a hypertensive disorder of pregnancy. The WHO
released a document in 2003 detailing the proper protocols and
techniques that should be utilized when measuring blood pres-
sure. While it is outside the scope of this document to present
a comprehensive guide to accurate blood pressure measurement,
several important points should be highlighted. Regardless of the
type of device used to measure blood pressure, accuracy should be
checked regularly by comparing the measurement device to a cali-
brated device, and health care providers should be properly trained
in taking blood pressure measurements. Blood pressure should be
34 (2016) 6069–6076measured with the patient in a seated position, with the arm at the
level of the heart. An appropriate cuff size should be chosen based
on the patient’s size (generally a length that is 1.5 times the cir-
cumference of the patient’s arm). The systolic blood pressure is the
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ccine 3ressure at which the ﬁrst sounds can be heard. The disappearance
f sounds, or the ﬁfth phase, is the best measurement of diastolic
lood pressure.
Blood pressure is considered elevated if the systolic blood pres-
ure is ≥140 mmHg  or the diastolic blood pressure is ≥90 mmHg,
ustained over time. The length of time that the blood pressure
hould remain elevated varies as well, from 15 min  [16] to 4 h
epending on which organization guidelines are followed [10]. The
righton Collaboration favors a longer time interval of sustained
lood pressure elevations. However, with respect to the poten-
ial logistical concerns in some settings of keeping a woman  for
bservation for several hours, we propose that a diagnosis of hyper-
ension be made if the systolic blood pressure is ≥140 mmHg  or the
iastolic blood pressure is ≥90 mmHg  on two measurements at a
inimum of one hour apart.
.3.4.2. Preeclampsia. Preeclampsia has conventionally been
eﬁned as the development of gestational hypertension and
roteinuria after 20 weeks gestation [2,10,14–16]. We  consider
reeclampsia as a systemic condition of endothelial dysfunction
n which hypertension is a primary presenting sign. Other organ
ystems will manifest this dysfunction in fashions speciﬁc to their
hysiology. Historically, microvascular dysfunction in the kidney
as been recognized as proteinuria.
Proteinuria can be quantiﬁed by 24 h urine collection, a spot
rotein:creatinine ratio, or with urinary dipstick. Proteinuria of
300 mg  in a 24 h urine specimen (the gold standard for measure-
ent of proteinuria), or ≥0.30 on a spot protein:creatinine ratio, or
1+ on a dipstick meets the criteria for preeclampsia [2,10,14–16].
outine visual dipstick urinalysis has been shown to have false
ositive rates at “1+” of 67–83%, and false negative rates at “nil”
r “trace” of 8–18% [17]. Automated urinalysis improves the sen-
itivity of this test to 74% [18]. The sensitivity and speciﬁcity of
he protein:creatinine ratio are higher at 93% and 92%, respec-
ively [18]. Given the potential variation in resources available to
est for proteinuria, the Brighton Collaboration will permit any of
hese measures of proteinuria, though 24 h urine collection and
rotein:creatinine ratio are preferred.
Preeclampsia can be further classiﬁed as having “severe fea-
ures” with development of laboratory abnormalities or symptoms.
he progression to preeclampsia with severe features represents
he clinical recognition of the additional involvement of mater-
al organ systems. Because certain clinical ﬁndings associated with
evere disease increase the morbidity and mortality of preeclamp-
ia [19], they are included in the Brighton Collaboration deﬁnition.
he diagnosis of severe preeclampsia requires new onset hyper-
ension (as described above) and one of the following criteria
numerated below. Given the multi-system nature of preeclamp-
ia, these will be presented by system:
NOTE that preeclampsia with severe features can be diagnosed
n the presence or absence of proteinuria.
Vascular:
 Severely elevated blood pressures, with systolic blood pressure
≥160 mmHg  and/or diastolic blood pressure ≥110 mmHg, which
is conﬁrmed after only minutes (to facilitate timely antihyper-
tensive treatment)
Neurologic:
 Development of a severe headache (which can be dif-
fuse, frontal, temporal or occipital) that generally does not
improve with over the counter pain medications (such as
acetaminophen/paracetamol)
C.E. Rouse et al. / Va Development of visual changes (including photopsia, scotomata,
cortical blindness) [20]
 Eclampsia, or new-onset grand mal  seizures in a patient with
preeclampsia, without other provoking factors (such as evidenceof cerebral malaria or preexisting seizure disorder). Seizures are
often preceded by headaches, visual changes or altered mental
status [21]
• Hematologic:
◦ New onset thrombocytopenia, with platelet count <100,000/L
• Gastrointestinal:
◦ New onset of nausea, vomiting, epigastric pain
◦ Transaminitis (AST and ALT elevated to twice the upper limit of
normal)
◦ Liver capsular hemorrhage or liver rupture
• Renal:
◦ Worsening renal function, as evidenced by serum creatinine level
greater than 1.1 mg/dL or a doubling of the serum creatinine
(absent other renal disease)
◦ Oliguria (urine output <500 mL/24 h)
• Respiratory:
◦ Pulmonary edema (conﬁrmed on clinical exam or imaging)
While complications of pregnancy such as intrauterine growth
restriction, placental abruption and stillbirth are utilized as diag-
nostic criteria for preeclampsia with severe features by some
societies [15,16], the Brighton Collaboration has chosen not to
include these in our deﬁnition since these conditions frequently
exist independently of the hypertensive disorders of pregnancy and
may represent a separate set of pathologies. We recommend that
these complications should certainly be reported as pregnancy out-
comes in the context of vaccine and other drug trials. The Brighton
Collaboration working groups on stillbirth, intrauterine growth
restriction and vaginal bleeding in pregnancy will have publications
forthcoming to help guide diagnosis of these related conditions.
http://www.brightoncollaboration.org.
1.3.5. Related conditions
1.3.5.1. HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelets) syn-
drome. HELLP syndrome is considered to be a subtype of severe
preeclampsia. The diagnosis is based on laboratory evaluation in
which all criteria (hemolysis, liver dysfunction, thrombocytopenia)
are met  [22,23]. It is important to note that hypertension may  be
absent in up to 15% of cases of HELLP syndrome. While we recognize
HELLP as part of the preeclampsia spectrum of disease, this diag-
nosis is not the focus of this document, and so will not be further
addressed.
1.3.5.2. Chronic hypertension. Chronic hypertension refers to ele-
vation in the systolic blood pressure to ≥140 mmHg  or the diastolic
blood pressure to ≥90 mmHg, sustained over a length of time (as
described above) that is diagnosed either prior to pregnancy or
prior to 20 weeks gestation. Hypertension that occurs in early ges-
tation is likely to predate pregnancy, hence the establishment of
20 weeks as a boundary for the diagnosis of chronic hyperten-
sion. Chronic hypertension progresses to preeclampsia in 10–50%
of cases, depending on the severity of the preexisting hypertension
[24]. The diagnosis of superimposed preeclampsia (preeclampsia
superimposed on chronic hypertension) is made based on the fol-
lowing criteria:
• preexisting hypertension (described above) PLUS any one of the
following:
◦ new onset proteinuria (as described above)
◦ worsening of preexisting proteinuria
◦ development of any of the laboratory abnormalities or clinical
ﬁndings consistent with severe preeclampsia
4 (2016) 6069–6076 60711.3.5.3. Postpartum preeclampsia. While some of the physiologic
changes of pregnancy take longer to return to a pre-pregnancy
state, the postpartum period, or puerperium, encompasses the
s
o
m
u
t
t
c
1
f
(
e
r
s
a
b
l
b
t
i
t
a
t
i
p
s
t
s
1
h
b
e
s
d
p
m
i
i
e
2
P
F
P
d
m
L
L
I
s
ccine 36  
ix weeks following delivery [25]. The exact incidence of new-
nset postpartum preeclampsia or hypertension is difﬁcult to
easure since most women do not return to their care provider
ntil 6 weeks after the delivery, but estimates range from 0.3%
o 27%[26]. The criteria for a postpartum diagnosis of the hyper-
ensive disorders of pregnancy are the same as the antepartum
riteria.
.3.6. Timing post immunization
We  postulate that a deﬁnition designed to be a suitable tool
or testing associations requires ascertainment of the outcome
e.g. a hypertensive disorder of pregnancy) independent from the
xposure (e.g. immunisations). Therefore, to avoid selection bias, a
estrictive time interval from immunization to onset of a hyperten-
ive disorder of pregnancy should not be an integral part of such
 deﬁnition. Instead, where feasible, details of this interval should
e assessed and reported as described in the data collection guide-
ines. Care should be taken to avoid creating spurious associations
etween vaccine administration and hypertensive disorders, given
hat vaccines are generally administered during speciﬁc times dur-
ng pregnancy. Case–control studies are needed to further evaluate
he potential link.
Further, hypertensive disorders of pregnancy are common,
ffecting up to 10% of pregnant women [1], and can occur outside
he controlled setting of a clinical trial or hospital. In some sett-
ngs it may  be impossible to obtain a clear timeline of the event,
articularly in less developed or rural settings. In order to avoid
electing against such cases, the Brighton Collaboration case deﬁni-
ion avoids setting arbitrary time frames, though the immunization
hould precede the hypertensive disorder.
.3.7. Differential diagnoses
Other diagnoses should be considered during the workup of
ypertension in pregnancy. The differential is broad, including
ut not limited to conditions such as preexisting renal dis-
ase, thrombotic thrombocytopenic purpura/hemolytic uremic
yndrome, acute fatty liver of pregnancy, primary liver disease, car-
iomyopathy, pheochromocytoma, and thyrotoxicosis. Seizures in
regnancy can be caused by a preexisting seizure disorder, cerebral
alaria, metabolic abnormalities, or cerebral anatomic abnormal-
ties such as a space-occupying lesion. Ensuring accurate diagnosis
s of great importance, as treatment can vary widely based on the
tiology of the patient’s symptoms.
. Case deﬁnitions
REECLAMPSIA
or All Levels of Diagnostic Certainty
reeclampsia is a clinical syndrome characterized by
pregnancy ≥20 weeks
AND
new onset hypertension (systolic blood pressure ≥140 mmHg  and/or
iastolic
blood pressure ≥90 mmHg) sustained on two measurements over a
inimum of 1 h
AND
new onset proteinuria
evel 1 of diagnostic certainty
proteinuria diagnosed with ≥300 mg  of protein on 24 h urine collection OR
≥0.3 on spot protein:creatinine ratio
evel 2 of diagnostic certainty
proteinuria diagnosed with ≥1+ protein on urine dipstick
nsufﬁcient evidence
C.E. Rouse et al. / Va072blood pressure cannot be measured OR
no proteinuria evaluation is available (note diagnosis of preeclampsia with
evere
features does not require proteinuria, see deﬁnition below)PREECLAMPSIA WITH SEVERE FEATURES
For All Levels of Diagnostic Certainty
Preeclampsia with severe features is a clinical syndrome characterized by
pregnancy ≥20 weeks
AND
new onset hypertension (systolic blood pressure ≥140 mmHg and/or
diastolic
blood pressure ≥90 mmHg) sustained on two measurements over a
minimum of 1 h
AND
At least one of the criteria for severe disease:
Level 1 of diagnostic certainty
At least one of the following:
Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110
mmHg, which is conﬁrmed after only minutes OR
Development of severe, persistent headache OR
Development of visual changes OR
Eclampsia OR
New onset thrombocytopenia (platelets <100,000/L) OR
New onset unremitting epigastric pain OR
AST and ALT elevated to twice upper limit of normal OR
Evidence of liver capsular hematoma or liver rupture (diagnosed on
clinical exam or with imaging) OR
Worsening renal function, as evidenced by serum creatinine level greater
than 1.1 mg/dL or a doubling of the serum creatinine (absent other renal
disease) or oliguria (<500 cc/24 h) OR
Pulmonary edema (conﬁrmed on imaging with chest X-ray, or on clinical
exam)
Level 2 of diagnostic certainty
new onset nausea and vomiting
Insufﬁcient evidence
blood pressure cannot be measured
GESTATIONAL HYPERTENSION
For All Levels of Diagnostic Certainty
Gestational Hypertension is a clinical syndrome characterized by
pregnancy ≥20 weeks
AND
new onset hypertension (systolic blood pressure ≥140 mmHg and/or
diastolic
blood pressure ≥90 mmHg) sustained on two measurements over a
minimum of 1 h
WITHOUT
severe features (see preeclampsia with severe features category) and
WITHOUT
proteinuria
Level 1 of diagnostic certainty
no proteinuria (as deﬁned by 24 h urine collection < 300 mg,  spot
protein:creatinine ratio <0.3)
Level 2 of diagnostic certainty
no proteinuria (as deﬁned by urine dipstick negative or trace)
Insufﬁcient evidence
blood pressure cannot be measured OR
no proteinuria evaluation is available
2.1. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case deﬁnition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis and
presentation. Neither case deﬁnition nor guidelines are intended to
guide or establish criteria for management of ill infants, children,
or adults. Both were developed to improve data comparability.
2.2. Periodic review
4 (2016) 6069–6076Similar to all Brighton Collaboration case deﬁnitions and guide-
lines, review of the deﬁnition with its guidelines is planned on a
regular basis (i.e. every three to ﬁve years) or more often if needed.
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ccine. Guidelines for data collection, analysis and presentation
f the hypertensive disorders of pregnancy, as presented in
ocument
It was the consensus of the Brighton Collaboration Hypertensive
isorders of Pregnancy Working Group to recommend the follow-
ng guidelines to enable meaningful and standardized collection,
nalysis, and presentation of information about these conditions.
owever, implementation of all guidelines might not be possible
n all settings. The availability of information may  vary depend-
ng upon resources, geographical region, and whether the source
f information is a prospective clinical trial, a post-marketing
urveillance or epidemiological study, or an individual report of
ypertension in pregnancy. Also, as explained in more detail in the
verview paper in this volume, these guidelines have been devel-
ped by this working group for guidance only, and are not to be
onsidered a mandatory requirement for data collection, analysis,
r presentation.
.1. Data collection
These guidelines represent a desirable standard for the col-
ection of data on availability following immunization to allow
or comparability of data, and are recommended as an addi-
ion to data collected for the speciﬁc study question and setting.
he guidelines are not intended to guide the primary repor-
ing of the hypertensive disorders of pregnancy to a surveillance
ystem or study monitor. Investigators developing a data col-
ection tool based on these data collection guidelines also need
o refer to the criteria in the case deﬁnition, which are not
epeated in these guidelines. The Brighton Collaboration has devel-
ped guidelines for data collection https://brightoncollaboration.
rg/public/resources/standards/guidelines.html; and data col-
ection forms https://brightoncollaboration.org/public/resources/
ata-collection-forms.html.
Guidelines below have been developed to address data ele-
ents for the collection of adverse event information as speciﬁed
n general drug safety guidelines by the International Conference
n Harmonization of Technical Requirements for Registration of
harmaceuticals for Human Use [27], and the form for reporting
f drug adverse events by the Council for International Organi-
ations of Medical Sciences [28]. These data elements include an
dentiﬁable reporter and patient, one or more prior immunisa-
ions, and a detailed description of the adverse event, in this case,
f a hypertensive disorder of pregnancy following immunization.
he additional guidelines have been developed as guidance for the
ollection of additional information to allow for a more comprehen-
ive understanding of development of the hypertensive disorders
f pregnancy following immunization.
.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
) Date of report.
) Name and contact information of person reporting2 and/or diag-
C.E. Rouse et al. / Vanosing the hypertensive disorder of pregnancy as speciﬁed by
country-speciﬁc data protection law.
) Name and contact information of the investigator responsible
for the subject, as applicable.
2 If the reporting center is different from the vaccinating center, appropriate and
imely communication of the adverse event should occur.4) Relation to the patient (e.g., immunizer [clinician, nurse], family
member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants,
as appropriate, the following information should be recorded:
5) Case/study participant identiﬁers (e.g. ﬁrst name initial followed
by last name initial) or code (or in accordance with country-
speciﬁc data protection laws).
6) Date of birth, age, and sex.
7) For infants: Gestational age and birth weight.
3.1.2.2. Clinical and immunization history. For all cases and/or
all study participants, as appropriate, the following information
should be recorded:
8) Past medical history, including hospitalisations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identiﬁcation of indicators for, or the absence of, a
history of allergy to vaccines, vaccine components or medica-
tions; food allergy; allergic rhinitis; eczema; asthma.
9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization including
prescription and non-prescription medication as well as med-
ication or treatment with long half-life or long term effect.
(e.g. immunoglobulins, blood transfusion and immunosup-
pressants).
10) Immunization history (i.e. previous immunisations and any
adverse event following immunization (AEFI)), in particular
occurrence of a hypertensive disorder in pregnancy after a pre-
vious immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
11) Date and time of immunization(s).
12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL,  0.5 mL,  etc.) and number of dose if
part of a series of immunisations against the same disease).
13) The anatomical sites (including left or right side) of all immu-
nisations (e.g. vaccine A in proximal left lateral thigh, vaccine
B in left deltoid).
14) Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
34 (2016) 6069–6076 60733.1.4. The adverse event
16) For all cases at any level of diagnostic certainty and for reported
events with insufﬁcient evidence, the criteria fulﬁlled to meet
the case deﬁnition should be recorded.
Speciﬁcally document:
17) Clinical description of signs and symptoms of the hypertensive
disorder of pregnancy, and if there was  medical conﬁrmation
of the event (i.e. patient seen by physician).
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8) Date/time of onset,3 ﬁrst observation4 and diagnosis,5 end of
episode6 and ﬁnal outcome.7
9) Concurrent signs, symptoms, and diseases.
0) Measurement/testing
• Values and units of routinely measured parameters (e.g. tem-
perature, blood pressure)–in particular those indicating the
severity of the event;
• Method of measurement (e.g. type of thermometer, oral or
other route, duration of measurement, etc.);
• Results of laboratory examinations, surgical and/or pathologi-
cal ﬁndings and diagnoses if present.
1) Treatment given for the hypertensive disorder of pregnancy,
especially any antihypertensive medication, magnesium sul-
fate and steroid medications.
2) Outcome7 at last observation.
3) Objective clinical evidence supporting classiﬁcation of the
event as “serious”.8
4) Exposures other than the immunization 24 h before and after
immunization (e.g. food, environmental) considered poten-
tially relevant to the reported event.
.1.5. Miscellaneous/general
5) The duration of surveillance for the hypertensive disorders of
pregnancy should be predeﬁned based on
• Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
• Biologic characteristics of the vaccine-targeted disease;
• Biologic characteristics of the hypertensive disorders of preg-
nancy including patterns identiﬁed in previous trials (e.g.
early-phase trials); and
• Biologic characteristics of the vaccinee (e.g. nutrition, underly-
ing disease like immunodepressing illness).
6) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. It should aim to continue
to resolution of the event.
7) Methods of data collection should be consistent within and
between study groups, if applicable.
8) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines
1–24.
9) Investigators of patients with a hypertensive disorder of preg-
nancy should provide guidance to reporters to optimize the
quality and completeness of information provided.
0) Reports of hypertensive disorders of pregnancy should be col-
lected throughout the study period regardless of the time
C.E. Rouse et al. / Va074elapsed between immunization and the adverse event. If this is
not feasible due to the study design, the study periods during
which safety data are being collected should be clearly deﬁned.
3 The date and/or time of onset is deﬁned as the time post immunization, when the
rst  sign or symptom indicative of a hypertensive disorder of pregnancy occurred.
his may  only be possible to determine in retrospect.
4 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom indicative
or  a hypertensive disorder of pregnancy can be used if date/time of onset is not
nown.
5 The date of diagnosis of an episode is the day post immunization when the event
et  the case deﬁnition at any level.
6 The end of an episode is deﬁned as the time the event no longer meets the case
eﬁnition at the lowest level of the deﬁnition.
7 E.g. recovery to pre-immunization health status, spontaneous resolution, ther-
peutic intervention, persistence of the event, sequelae, death.
8 An AEFI is deﬁned as serious by international standards if it meets one or
ore of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
equires inpatient hospitalization or results in prolongation of existing hospitaliza-
ion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
nomaly/birth defect, (6) is a medically important event or reaction.3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on the hypertensive disorders of pregnancy to allow for
comparability of data, and are recommended as an addition to data
analyzed for the speciﬁc study question and setting.
31) Reported events should be classiﬁed in one of the following
ﬁve categories including the three levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
Event classiﬁcation in 5 categories9
Event meets case deﬁnition
1) Level 1: Criteria as speciﬁed in the Hypertensive Disorders of
Pregnancy case deﬁnition
2) Level 2: Criteria as speciﬁed in the Hypertensive Disorders of
Pregnancy case deﬁnition
Event does not meet case deﬁnitionAdditional categories for
analysis
3) Reported hypertensive disorder of pregnancy with insufﬁcient
evidence to meet the case deﬁnition10,11
4) Not a case of a hypertensive disorder of pregnancy
32) The interval between immunization and reported hyperten-
sive disorder of pregnancy could be deﬁned as the date/time
of immunization to the date/time of onset3 of the ﬁrst symp-
toms and/or signs consistent with the deﬁnition. If few cases
are reported, the concrete time course could be analyzed for
each; for a large number of cases, data can be analyzed in the
following increments:
Subjects with a hypertensive disorder of pregnancy by inter-
val to presentation
Interval* Number
<1  week after immunization
<1 week <1 month after immunization
1 month – <3 months after immunization
<3 months – <6 months after immunization
Every 3 months increments thereafter through 6 weeks postpartum
Total
33) The duration of a possible hypertensive disorder of pregnancy
34 (2016) 6069–6076could be analyzed as the interval between the date/time of
onset2 of the ﬁrst symptoms and/or signs consistent with
the deﬁnition and the end of episode6 and/or ﬁnal outcome.7
9 To determine the appropriate category, the user should ﬁrst establish, whether
a  reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level two. If the lowest applicable level of diagnostic certainty of the
deﬁnition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classiﬁed in the next category.
This  approach should be continued until the highest level of diagnostic certainty
for a given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met  and
the  event should be classiﬁed in additional categories four or ﬁve.
10 If the evidence available for an event is insufﬁcient because information is miss-
ing,  such an event should be categorized as “Reported hypertensive disorder of
pregnancy with insufﬁcient evidence to meet the case deﬁnition”.
11 An event does not meet the case deﬁnition if investigation reveals a negative
ﬁnding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classiﬁed as “Not a case of a hypertensive disorder of preg-
nancy”.
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van  Goor K, et al. Adjuvanted vaccines in pregnancy: no evidence for effect of
the  adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-
uterine growth restriction. Eur J Obstet Gynecol Reprod Biol 2015;187:14–9.
[7] Millar MR,  Sanz MG.  The administration of pertussis vaccine to pregnant
women  was associated with a small increased risk of chorioamnionitis, but
ccineWhatever start and ending are used, they should be used con-
sistently within and across study groups.
4) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
5) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases is pre-
sented, the respective values or time course can be presented
individually.
6) Data on hypertensive disorders of pregnancy obtained from
subjects receiving a vaccine should be compared with those
obtained from an appropriately selected and documented con-
trol group(s) to assess background rates of hypersensitivity in
non-exposed populations, and should be analyzed by study
arm and dose where possible, e.g. in prospective clinical trials.
.3. Data presentation
These guidelines represent a desirable standard for the pre-
entation and publication of data on hypertensive disorders of
regnancy following immunization to allow for comparability of
ata, and are recommended as an addition to data presented for the
peciﬁc study question and setting. Additionally, it is recommended
o refer to existing general guidelines for the presentation and pub-
ication of randomized controlled trials, systematic reviews, and
eta-analyses of observational studies in epidemiology (e.g. state-
ents of Consolidated Standards of Reporting Trials (CONSORT), of
mproving the quality of reports of meta-analyses of randomized
ontrolled trials (QUORUM), and of Meta-analysis Of Observational
tudies in Epidemiology (MOOSE), respectively) [29–31].
7) All reported events of hypertensive disorders of pregnancy
should be presented according to the categories listed in guide-
line 31.
8) Data on possible hypertensive disorders of pregnancy should
be presented in accordance with data collection guidelines
1–24 and data analysis guidelines 31–36.
9) Terms to describe hypertensive disorders of pregnancy such
as “low-grade”, “moderate”, “high”, or “signiﬁcant” are highly
subjective, prone to wide interpretation, and should be
avoided, unless clearly deﬁned.
0) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomi-
ator data are usually not readily available, attempts should be
ade to identify approximate denominators. The source of the
enominator data should be reported and calculations of estimates
e described (e.g. manufacturer data like total doses distributed,
eporting through Ministry of Health, coverage/population based
ata, etc.).
) The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
) If the distribution of data is skewed, median and range are usually
the more appropriate statistical descriptors than a mean. How-
ever, the mean and standard deviation should also be provided.
C.E. Rouse et al. / Va) Any publication of data on the hypertensive disorders of preg-
nancy should include a detailed description of the methods used
for data collection and analysis as possible. It is essential to spec-
ify:• The study design;
• The method, frequency and duration of monitoring for the hyper-
tensive disorders of pregnancy;
• The trial proﬁle, indicating participant ﬂow during a study includ-
ing drop-outs and withdrawals to indicate the size and nature of
the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardized question-
naire, diary card, report form);
• Whether the day of immunization was considered “day one” or
“day zero” in the analysis;
• Whether the date of onset3 and/or the date of ﬁrst observation4
and/or the date of diagnosis5 was  used for analysis; and
• Use of this case deﬁnition for the hypertensive disorders of preg-
nancy, in the abstract or methods section of a publication.12
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